Item 7.01 Regulation FD Disclosure.

On July 27, 2021, certain existing institutional shareholders of Certara, Inc. (the "Company"), including a shareholder affiliated with EQT AB ("EQT"), entered into an agreement to sell an aggregate of 9,615,384 shares at $26 per share to an affiliate of Mubadala Investment Company. The transaction is scheduled to close on August 2, 2021. EQT will remain a significant shareholder in Certara, Inc. after the transaction.

On July 27, 2021, the Company issued a press release announcing the transaction. A copy of that press release is attached as Exhibit 99.1 hereto and is incorporated by reference herein.

The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibit 99.1 hereto) is being "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.





Forward-Looking Statements

This current report contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. These factors include, but are not limited to, (i) the failure of the transaction described above to close, or a delay in the anticipated closing date; (ii) any deceleration in, or resistance to, the acceptance of model-informed biopharmaceutical discovery; (iii) increasing competition, regulation and other cost pressures within the pharmaceutical and biotechnology industries; (iv) our ability to compete within our market; (v) changes or delays in government regulation relating to the biopharmaceutical industry and (vi) changes in EQT's plans with respect to the Company. In some cases, forward-looking statements can be identified by words or phrases such as "may," "will," "expect," "anticipate," "target," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. All information provided in this press release is as of the date of this press release, and Certara undertakes no duty to update such information, except as required under applicable law.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits.


Exhibit No.                               Description
  99.1              Press release issued by Certara, Inc.

104               Cover Page Interactive Data File (formatted as Inline XBRL).

© Edgar Online, source Glimpses